Pfizer and ExonHit to research Alzheimer's disease biomarkers
This article was originally published in Scrip
Executive Summary
France's ExonHit Therapeutics has received a boost for its Genome-Wide SpliceArray (GWSA) platform, after Pfizer entered a research agreement with the company to identify biomarkers for Alzheimer's disease.